Copper Door Counseling | |
3055 S Us Highway 33 Albion IN 46701-9620 | |
(260) 239-7956 | |
(260) 638-0280 |
Full Name | Copper Door Counseling |
---|---|
Speciality | Counselor - Mental Health |
Location | 3055 S Us Highway 33, Albion, Indiana |
Authorized Official Name and Position | Jessica L Smith (OWNER) |
Authorized Official Contact | 2602397956 |
Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
Mailing Address | Practice Location Address |
---|---|
Copper Door Counseling Po Box 143 Wolflake IN 46796-0143 Ph: (260) 239-7956 | Copper Door Counseling 3055 S Us Highway 33 Albion IN 46701-9620 Ph: (260) 239-7956 |
NPI Number | 1730884537 |
---|---|
Provider Enumeration Date | 04/03/2023 |
Last Update Date | 04/03/2023 |
Certification Date | 04/01/2023 |
Identifier | Type | State | Issuer |
---|---|---|---|
1730884537 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YA0400X | Counselor - Addiction (substance Use Disorder) | (* (Not Available)) | Secondary |
101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
News Archive
The Washington Post: "The next 48 hours will be critical to the fate of health-care reform in the Senate, as Democratic leaders struggle to settle disputes that stand in the way of holding a final vote this year on the massive package reports on the distance among senators that has to be bridged before a bill can pass."
In an abstract being presented today during the American College of Rheumatology Annual Scientific Meeting in Chicago, Dr. S. Sam Lim of Emory University School of Medicine will present data showing that black women have a significantly higher incidence of systemic lupus erythematosus than most reports in the scientific literature.
Antidepressants are effective against depression in patients suffering from physical illnesses, according to a new systematic review by Cochrane researchers at King's Health Partners Academic Health Sciences Centre in the UK. The researchers found the drugs were more effective than placebos at treating depression in these patients.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has announced further positive data on the first forty subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma, with an objective response ("OR") observed in 61% of subjects and a mean Progression Free Survival ("PFS") of at least 11.1 months among those subjects achieving an OR.
› Verified 5 days ago